Xencor, Inc.

NASDAQ:XNCR

Biotechnology

Healthcare
$34.39 -1.03%

-$0.13 today

Market cap
$2.58B
Beta
0.93
P/E (TTM)
-5.5
EPS (TTM)
-$2.29
52W Low $6.92High $18.69

Volume 0.87M

Average 0.80M

XNCR Interest Income

Income earned on cash, deposits, and investments held by the company.

Xencor, Inc.NASDAQ: XNCR

Interest Income · Q2 FY2026 · quarter ended Jun 2026

Interest income declines year over year

Q2 FY2026 interest income of $4.8M fell 33.8% year over year, behind the -24.6% change in trailing-twelve-month interest income. Sequentially, it fell 12.1% from the prior quarter. Over 3 fiscal years it compounded at +78.8% a year.

Context

  • Interest income amounted to 21.9% of revenue in FY2025, down 7.0 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -33.8% toward the trailing-twelve-month pace of -24.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$4.8M-12.1% QoQ
Last fiscal yearDec 2025
$27.52M-13.8% YoY
LTMJun 2026
$23M-24.6% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.8%——
1 year-13.8%——
3-year CAGR+78.8%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
27.52M USD
Year-over-year change
-13.8%
4-year CAGR
+137.7%

Interest Income vs competitors

How XNCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -24.6% is the 5th highest of 9, against a peer median of -24.7%.
  • Interest income amounts to 21.9% of revenue for XNCR, versus a peer median of 19.5%.
XNCR Competitors
Interest Income for XNCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GMABGenmab A/SLTM Jun 2026$129.91M USD—-24.7%3.1%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$25.4M USD-19.9%+114.3%22679.5%
XNCRXencor, Inc.LTM Jun 2026$23M USD-24.6%+78.8%21.9%
NKTRNektar TherapeuticsLTM Jun 2026$19.18M USD+70.9%+15.5%35.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$18.56M USD-20.1%+84.3%2.6%
IMCRImmunocore Holdings plcLTM Mar 2026$14.94M USD-30.5%+63.7%3.9%
ADAGAdagene Inc.LTM Jun 2024$6.08M USD—+82.7%745.4%
MGNXMacroGenics, Inc.LTM Mar 2026$5.93M USD-29.4%+26.0%3.8%
IMMPImmutep LimitedFY2025A$5.25M AUD+35.2%+186.0%104.1%
CGENCompugen Ltd.LTM Mar 2026$2.66M USD-49.0%+45.3%3.7%
IPHAInnate Pharma S.A.FY2025€1.32M EUR-45.9%+34.1%47.3%
Peer median (excluding XNCR) —-24.7%+54.5%19.5%

Competitors are the stored peer set for XNCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue275.11M164.58M174.62M110.49M125.58M
Cost of Revenue192.51M199.56M0227.69M10.51M
Gross Profit82.6M(34.98M)174.62M(117.19M)115.06M
Gross Margin30.0%-21.3%100.0%-106.1%91.6%
Research & Development192.51M199.56M253.6M227.69M239.43M
Selling, General & Admin38.84M47.49M53.38M58.89M63.64M
Operating Expenses38.84M47.49M306.98M61.22M292.57M
Depreciation & Amortization7.49M8.8M11.5M12.11M10.51M
EBITDA90.14M(45.7M)(101.96M)(186.17M)(46.98M)
EBITDA Margin32.8%-27.8%-58.4%-168.5%-37.4%
Operating Income43.77M(82.47M)(132.36M)(178.41M)(177.5M)
Operating Margin15.9%-50.1%-75.8%-161.5%-141.4%
Interest Income862K4.82M18.63M31.93M27.52M
Interest Expense13K0036.64M31.93M
Other Income / Expenses38.86M27.97M12.73M(56.52M)87.87M
Income Before Tax82.63M(54.51M)(119.63M)(234.92M)(89.42M)
Pre-Tax Margin30.0%-33.1%-68.5%-212.6%-71.2%
Income Tax Expense0673K13.66M1.62M2.5M
Net Income82.63M(55.18M)(133.13M)(232.62M)(91.92M)
Net Margin30.0%-33.5%-76.2%-210.5%-73.2%
EPS (Basic)1.42(0.93)(2.08)(3.58)(1.24)
EPS (Diluted)1.37(0.93)(2.08)(3.58)(1.24)
Weighted Avg Shares58.38M59.65M60.5M65.04M74.24M
Weighted Avg Shares (Diluted)60.5M59.65M60.5M65.04M74.24M

Xencor, Inc.

NASDAQ:XNCR

Intrinsic Alpha fair value

Locked

Current Price

$34.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.